Navigation Links
IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference
Date:6/10/2009

NORTH HOLLYWOOD, Calif., June 10 /PRNewswire-FirstCall/ -- IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading national physician group practice company, announced today that management is scheduled to present at the Jefferies 3rd Annual Healthcare Conference, to be held June 17-18, 2009 in New York City. Adam Singer, M.D., Chairman and CEO, and Jeff Taylor, President and COO, will be speaking at the conference. IPC's presentation will take place at 3:15 P.M. Eastern time on Thursday, June 18th.

A live Web cast of the presentation will also be available by visiting the investor relations section of the Company's Web site. A replay of the presentation will be available for 30 days.

About IPC The Hospitalist Company

IPC The Hospitalist Company, Inc. (Nasdaq: IPCM) is a leading national physician group practice company focused on the delivery of hospitalist medicine services. IPC's physicians and affiliated providers manage the care of hospitalized patients in coordination with primary care physicians and specialists. The Company provides its hospitalists with the comprehensive training, information technology, and management support systems necessary to improve the quality and reduce the cost of inpatient care in the facilities it serves. For more information, visit the IPC website at www.hospitalist.com.

    Contacts:
    Devra Shapiro                       Amy Glynn/Nick Laudico
    IPC The Hospitalist Company, Inc.   The Ruth Group
    (818) 766-3502                      646-536-7023/7030
                                        aglynn@theruthgroup.com
           
'/>"/>
SOURCE IPC The Hospitalist Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Availability of diagnostic tests drive success in hospitalist-run short-stay units
2. IPC The Hospitalist Company, Inc. to Present at Citis 2009 Healthcare Services Day
3. IPC The Hospitalist Company CEO Adam Singer Named One of 50 Most Powerful Physician Executives
4. IPC The Hospitalist Company, Inc. to Present at Deutsche Banks 34th Annual Health Care Conference
5. IPC The Hospitalist Company Reports Record First Quarter 2009 Results
6. IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results
7. IPC The Hospitalist Company Presents IPC Hospitalist of the Year Award to Tim Osonma, M.D.
8. IPC The Hospitalist Company Acquires Arizona Practice
9. Spokane Hospitals Engage Sound Inpatient Physicians(TM) as Hospitalists in Spokane
10. IPC The Hospitalist Company Adopts E-Proxy to Reduce Environmental Impact
11. IPC The Hospitalist Company Reports Record Fourth Quarter and Full Year 2008 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...firm Replikins Ltd. today issued its latest bioche... shows that the lethality of the virus has dropped...s current outbreak in the spring of 2009 to restin... The H1N1 infectivity count, however, remains incr...ovember 27, 2009 -- Biotech firm Replikins Ltd., w...
(Date:11/27/2009)...7/PRNewswire-FirstCall/--ShamirOpticalIndustryLtd....vativeproductsandtechnologytotheophthalmiclensmark...dadividenddistributioninanaggregateamountofUS$10mi...er25,2009representativerateofexchange),orapproxima...25,2009representativerateofexchange)perordinarysha...
(Date:11/27/2009)...ealth™ announced today that Spectrum Health ...d Enterprise orthopedic templating solution and it... (PRWEB) November 27, 2009 -- Voyant...h (Grand Rapids, Michigan) has licensed its Trauma...its TraumaCad Extend workflow solution, to allow i...
(Date:11/26/2009)...wswire/--ThediabetespopulationintheUnitedStateswil...ndingonthediseaseisprojectedtohit$336billion,upfro...ecemberissueof DiabetesCare .TheNational ChangingD...commissionedtheanalysisbyateamfromtheUniversityofC...ericanslivingwithdiabeteswillrisefrom23.7millionin...
(Date:11/26/2009)...letters from the North Pole, Textsanta.net lets pa...Santa , North Pole, AK (P...ciencies at the North Pole Santa Claus has added S...he globe informed of his Christmas progress at the...epartment have identified a large and growing perc...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...ormone replacement therapy (HRT) should not be pre...opause to help prevent chronic conditions such as ... view that HRT is a safe short term treatment for ... postmenopausal women taking HRT had more heart at...
... the UK could prevent up to 3200 deaths from heart...n the Journal of Epidemiology and Community Health... is already applied to confectionery, ice cream, s...te the likely impact of price rises on demand of a...
...University study published in the July issue of th...s seldom require screening for substance abuse an... improve detection. This may be a missed ...nstance Horgan, director of the Institute for Beha...
...lobin levels to help dialysis patients One... anemia. In order to live a better quality life, d...ate hemoglobin level. Thus anemia correction is a ...ow is the drug called erythropoiesis-stimulating a...
...ow and middle-income countries can turn out econom...clusion was reached by A UCSF-led team of researc...underway in countries like India, South Africa, Ug...th the recent report from the Global HIV Preventio...
...ts reaction to a particular variety of sugar prese...ording to Biology textbooks neutrophils are regard...rm an integral part of blood. They are the policem...uder that invades the body. A new study shows that...
Other Medicine News:Health News:Study Confirms No HRT Benefit for Older Women 2Health News:Study Confirms No HRT Benefit for Older Women 3Health News:Fat Tax Could Avoid Considerable Amount of Heart Attack and Stroke Deaths Annually 2Health News:Screening for Behavioral Health 2Health News:Analysis of Hemoglobin Level Control in Dialysis Patients 2Health News:Analysis of Hemoglobin Level Control in Dialysis Patients 3Health News:HIV Prevention Programs on a Massive Scale Turn Out Economical 2Health News:WBC Selective About Sugar 2
(Date:11/25/2009)...25/PRNewswire/--RegadoBiosciences,aprivatelyheldco...withactivecontrolagents,announcedthatDavidMazzo,Ph...y21stAnnualHealthCareConferenceattheNewYorkPalaceH...nat1:10pm(EST)onTuesday,December1andwillincludeano...developmentprogram,theanticoagulantsystem,REG1.The...
(Date:11/25/2009)...5/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ...ebloodanalysissystems,announcedtodaythatClintSever...the21stAnnualPiperJaffrayHealthCareConferenceonWed...lbeheldattheNewYorkPalaceHotelinNewYorkCity. ,,...dmarketsportablebloodanalysissystemsforuseinanyvet...
(Date:11/25/2009).../PRNewswire/--CempraPharmaceuticalsInc.todayannoun...tiveofficer,willpresentatthePiperJaffray21stAnnual...tTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernandeswi...ticclinicalprogramsforthetreatmentofdrug-resistant...uticals ,, Foundedin2006,CempraPharmaceuticals...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 1Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 2Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 1Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 2Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 4
... Dec. 9 Portola,Pharmaceuticals, a biopharmaceuti...de significant advances in cardiovascular disease,...that it has initiated patient enrollment in,INNOVA...28, the Company,s,novel P2Y12 ADP receptor antagon...s coronary intervention (PCI). , "With the i...
...nnium: The Takeda Oncology Company today reported ...ients from the large, international Phase III VIST...for patients with previously untreated multiple my...P). The VELCADE combination demonstrated consisten...ose with poor prognostic characteristics, such as ...
Other Medicine Technology:Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 2Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
Anorectal Water Perfused Catheters
AnorectalSolid State Manometry Catheters
Multi-Use Adult Anorectal Water Perfused Catheters
Multi-Use Adult Esophageal Water Perfused Catheters
Medicine Products: